Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, has launched Vancomycin hydrochloride for injection, USP, an anti-infective, in a 10 gram preservative-free pharmacy bulk package presentation.
The Vancomycin 10 gram presentation is an addition to Sagent's Vancomycin 5 gram pharmacy bulk package offering. According to IMS, for the 12 months ending February 2015, the US market for Vancomycin approximated $196 million of which over fifty per cent of the sales was pharmacy bulk package bottles. As with all products in Sagent's portfolio, Vancomycin features Sagent's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.
Vancomycin hydrochloride for injection, USP is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (ß-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs.